NATIONAL CANCER INSTITUTE

Researchers at Moffitt Cancer Center demonstrated that combining avelumab immunotherapy with whole brain radiotherapy showed promising safety and efficacy in treating leptomeningeal disease, a devastating cancer complication.

Dogwood Therapeutics acquired exclusive worldwide rights to SP16, a first-in-class LRP1 agonist for treating cancer-related pain, through an all-stock transaction with Serpin Pharma.

ClearNote Health has received United Kingdom Conformity Assessed (UKCA) marking for its Avantect multi-cancer detection test and Avantect ovarian cancer test, enabling market access in the UK.

BriaCell Therapeutics announced publication of mechanism of action data for its Bria-OTS+ immunotherapy platform in JCI Insight, conducted in collaboration with the National Cancer Institute.

BriaCell Therapeutics has been awarded a $2,054,651 non-dilutive grant from the National Cancer Institute to advance Bria-PROS+, a next-generation personalized off-the-shelf immunotherapy for prostate cancer.

Breast cancer patients in a remote weight-loss intervention program lost an average of 4.7% of their baseline body weight after one year, while control group participants gained 1% of their baseline weight.

University of Oklahoma researchers developed Smart-T, a real-time adaptive smartphone app that nearly doubled smoking cessation rates compared to a static app in a clinical trial of 454 low-income smokers.

RenovoRx achieved over $400,000 in second quarter 2025 revenue from commercial sales of its FDA-cleared RenovoCath drug-delivery device, marking strong growth in its first two full quarters of commercialization.

ChatGPT-4 demonstrated superior performance over ChatGPT-3.5 in screening patients for clinical trials, achieving 84% accuracy with better sensitivity and specificity balance.

Radiopharm Theranostics has appointed Dr. Oliver Sartor, an internationally recognized medical oncologist specializing in prostate cancer and radiopharmaceutical therapies, to its Scientific Advisory Board.